ELAN CEO Jeffrey Simmons acquires 129.2829 deferred stock units

Q: How many deferred stock units does the ELAN CEO hold after the transaction?

The filing shows 18,099.5935 deferred stock units beneficially owned directly following the transaction.

Q: What is the price listed for the ELAN derivative security?

The filing lists a $21.42 price of the derivative security.

Q: What do Elanco deferred stock units represent?

Each unit represents the right to receive one share of common stock or the cash equivalent .

Q: When do ELAN deferred stock units settle?

They settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.

Q: Who is the reporting person in this ELAN Form 4?

The reporting person is Jeffrey N. Simmons , Elanco’s President, CEO and Director.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Elanco Animal Health (ELAN): CEO Form 4 filing. President, CEO and Director Jeffrey N. Simmons reported an acquisition of 129.2829 deferred stock units on 10/17/2025 (Transaction Code A). The filing shows a $21.42 price of the derivative security and a post‑transaction balance of 18,099.5935 deferred stock units held directly.

Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year in accordance with the company’s Executive Deferral and Stock Match Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simmons Jeffrey N

Role PRESIDENT, CEO AND DIRECTOR

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	129.2829	$21.42	$3K

Holdings After Transaction: Deferred Stock Units — 18,099.5935 shares (Direct)

Footnotes (2)

F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/21/2025 - 04:21 PM

FAQ

What did Elanco (ELAN) report in this Form 4?

Jeffrey N. Simmons, President, CEO and Director, reported acquiring 129.2829 deferred stock units on 10/17/2025 (Code A).

How many deferred stock units does the ELAN CEO hold after the transaction?

The filing shows 18,099.5935 deferred stock units beneficially owned directly following the transaction.

What is the price listed for the ELAN derivative security?

The filing lists a $21.42 price of the derivative security.

What do Elanco deferred stock units represent?

Each unit represents the right to receive one share of common stock or the cash equivalent.

When do ELAN deferred stock units settle?

They settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.

Who is the reporting person in this ELAN Form 4?

The reporting person is Jeffrey N. Simmons, Elanco’s President, CEO and Director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last)

(First)

(Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS

46221

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	10/17/2025		A		129.2829		⁽²⁾	⁽²⁾	Common Stock	129.2829	$21.42	18,099.5935	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR